Last reviewed 2026-04-23 · How we verify

SSR591813L (dianicline)

Sanofi · Phase 3 active Small molecule

SSR591813L (dianicline) is a norepinephrine reuptake inhibitor Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Treatment of attention deficit hyperactivity disorder (ADHD).

SSR591813L (dianicline) is a norepinephrine reuptake inhibitor.

SSR591813L (dianicline) is a norepinephrine reuptake inhibitor. Used for Treatment of attention deficit hyperactivity disorder (ADHD).

At a glance

Generic name	SSR591813L (dianicline)
Sponsor	Sanofi
Drug class	norepinephrine reuptake inhibitor
Target	norepinephrine transporter
Modality	Small molecule
Therapeutic area	Central Nervous System
Phase	Phase 3

Mechanism of action

Dianicline works by selectively inhibiting the norepinephrine transporter, increasing the concentration of norepinephrine in the synaptic cleft, which enhances the activity of norepinephrine in the brain. This is thought to improve cognitive function and potentially treat conditions such as attention deficit hyperactivity disorder (ADHD).

Approved indications

Treatment of attention deficit hyperactivity disorder (ADHD)

Common side effects

Nausea
Headache
Dizziness
Fatigue

Key clinical trials

Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SSR591813L (dianicline) CI brief — competitive landscape report
SSR591813L (dianicline) updates RSS · CI watch RSS
Sanofi portfolio CI

Frequently asked questions about SSR591813L (dianicline)

What is SSR591813L (dianicline)?

SSR591813L (dianicline) is a norepinephrine reuptake inhibitor drug developed by Sanofi, indicated for Treatment of attention deficit hyperactivity disorder (ADHD).

How does SSR591813L (dianicline) work?

SSR591813L (dianicline) is a norepinephrine reuptake inhibitor.

What is SSR591813L (dianicline) used for?

SSR591813L (dianicline) is indicated for Treatment of attention deficit hyperactivity disorder (ADHD).

Who makes SSR591813L (dianicline)?

SSR591813L (dianicline) is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

What drug class is SSR591813L (dianicline) in?

SSR591813L (dianicline) belongs to the norepinephrine reuptake inhibitor class. See all norepinephrine reuptake inhibitor drugs at /class/norepinephrine-reuptake-inhibitor.

What development phase is SSR591813L (dianicline) in?

SSR591813L (dianicline) is in Phase 3.

What are the side effects of SSR591813L (dianicline)?

Common side effects of SSR591813L (dianicline) include Nausea, Headache, Dizziness, Fatigue.

What does SSR591813L (dianicline) target?

SSR591813L (dianicline) targets norepinephrine transporter and is a norepinephrine reuptake inhibitor.

Drug class: All norepinephrine reuptake inhibitor drugs
Target: All drugs targeting norepinephrine transporter
Manufacturer: Sanofi — full pipeline
Therapeutic area: All drugs in Central Nervous System
Indication: Drugs for Treatment of attention deficit hyperactivity disorder (ADHD)
Compare: SSR591813L (dianicline) vs similar drugs
Pricing: SSR591813L (dianicline) cost, discount & access